Great Lakes Advisors LLC Makes New $16.04 Million Investment in Elanco Animal Health Incorporated (NYSE:ELAN)

Great Lakes Advisors LLC bought a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,111,772 shares of the company's stock, valued at approximately $16,043,000. Great Lakes Advisors LLC owned about 0.22% of Elanco Animal Health as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in ELAN. Primecap Management Co. CA grew its stake in shares of Elanco Animal Health by 2.9% in the fourth quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company's stock worth $753,945,000 after acquiring an additional 1,431,665 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Elanco Animal Health by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company's stock worth $737,083,000 after acquiring an additional 467,196 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Elanco Animal Health by 4.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company's stock worth $360,425,000 after acquiring an additional 852,281 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Elanco Animal Health by 33.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 15,095,179 shares of the company's stock worth $224,920,000 after acquiring an additional 3,816,514 shares in the last quarter. Finally, Ancora Advisors LLC grew its stake in shares of Elanco Animal Health by 1.4% in the first quarter. Ancora Advisors LLC now owns 10,641,194 shares of the company's stock worth $173,239,000 after acquiring an additional 143,326 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Analysts Set New Price Targets

ELAN has been the subject of several research reports. Barclays dropped their price target on shares of Elanco Animal Health from $23.00 to $21.00 and set an "overweight" rating for the company in a research note on Friday, June 28th. Piper Sandler lowered their target price on shares of Elanco Animal Health from $19.00 to $16.00 and set a "neutral" rating for the company in a research note on Monday, July 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.57.

Insider Activity

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 100,000 shares of Elanco Animal Health stock in a transaction dated Monday, August 12th. The stock was acquired at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the acquisition, the chief executive officer now owns 145,000 shares of the company's stock, valued at $1,886,450. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Michael J. Harrington purchased 3,500 shares of the business's stock in a transaction that occurred on Thursday, August 22nd. The stock was purchased at an average cost of $14.85 per share, with a total value of $51,975.00. Following the completion of the acquisition, the director now directly owns 81,094 shares of the company's stock, valued at approximately $1,204,245.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeffrey N. Simmons purchased 100,000 shares of the business's stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 145,000 shares of the company's stock, valued at $1,886,450. The disclosure for this purchase can be found here. Corporate insiders own 0.57% of the company's stock.

Elanco Animal Health Stock Performance

ELAN traded down $0.26 on Friday, reaching $15.09. The company had a trading volume of 3,600,515 shares, compared to its average volume of 4,795,414. Elanco Animal Health Incorporated has a 1 year low of $8.52 and a 1 year high of $18.80. The stock has a market capitalization of $7.46 billion, a PE ratio of -5.69, a P/E/G ratio of 1.54 and a beta of 1.40. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92. The stock has a 50-day moving average price of $13.83 and a 200-day moving average price of $15.26.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The firm had revenue of $1.18 billion during the quarter, compared to analysts' expectations of $1.15 billion. During the same period in the previous year, the company earned $0.18 earnings per share. Elanco Animal Health's quarterly revenue was up 12.0% compared to the same quarter last year. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.